Collegium Pharmaceutical, Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Collegium Pharmaceutical, Inc. (COLL) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five of $102.64 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue · last filed 2026-08-06
- 2026-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five $102.64M.
- 2025-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five $103.35M.
- 2025-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five $95.14M.
- 2025-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five $65.65M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five |
|---|---|
| 2026-03-31 | $102.64M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $103.35M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $95.14M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $65.65M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $56.17M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $43.72M 10-K · filed 2026-02-26 |
| 2024-09-30 | $38.60M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $37.66M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $29.42M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $14.66M 10-K · filed 2025-02-27 |
| 2023-09-30 | $5.92M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $6.34M 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |